Transcriptomics Market Report by Type, Technology, Application, End User, and Region 2025-2033

The global transcriptomics market size reached USD 7.6 Billion in 2024. Looking forward, the market is projected to reach USD 12.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.3% during 2025-2033. The market is witnessing steady growth, mainly boosted by innovations in bioinformatics and sequencing technologies. Moreover, amplifying research in personalized medicine and genomics further fuels demand. At present, North America holds the largest market share, attributed to the presence of prominent companies and increased investments in biotechnology sector.

The transcriptomics market demand is driven by the ongoing advancements in next-generation sequencing (NGS) technologies that have enhanced the accuracy and efficiency of gene expression analysis. In addition, the rising demand for personalized medicine is encouraging the use of transcriptomics to identify biomarkers for targeted therapies, aiding the market growth. Moreover, the increasing investments in genomic research by government and private entities are fueling innovation in the field, thus contributing to the market expansion. For instance, in January 2025, Truveta entered into a $320 million funding agreement for the building of what will be the largest public genomic database in the world at 10 million genomic sequences.

This involves investors such as Regeneron Pharmaceuticals and Illumina and aims at surpassing the discovery of drugs and correspondent care of patients by detecting genetic tendencies or disease mutations. Furthermore, collaborations between academia and industry are fueling product development and commercialization, thus catalyzing the market growth.

The United States holds 82.90% of the market share. The transcriptomics market growth in this region is propelled by a robust healthcare infrastructure that supports advanced research and development (R&D). In line with this, the growing focus on precision agriculture and plant genomics is expanding transcriptomics applications in agrigenomics, fostering market demand. Concurrently, the rising public and private funding for rare disease research is driving the demand for innovative transcriptomic tools. Additionally, the increasing utilization of single-cell transcriptomics in immunology and oncology is fostering growth.

For example, Illumina collaborated with the Broad Institute to design new gene sequencing kits employing CRISPR technology in PerturbSeq screening. Such a partnership is expected to enhance large-scale gene sequencing, which has a dramatic effect on disease and treatment modeling. Moreover, the strong presence of cutting-edge biopharmaceutical companies is boosting the adoption of transcriptomic technologies and strengthening the market share. Apart from this, increasing government initiatives promoting biotechnology and genomics education are cultivating a skilled workforce, thereby propelling the market forward.

Transcriptomics Market Trends:

Integration of Transcriptomics with ML and AI

According to the transcriptomics market forecast, the incorporation of machine learning (ML) and artificial intelligence (AI) is anticipated to revolutionize data analysis in this field. AI-powered tools can effectively interpret large datasets, diagnosing complicated correlations as well as patterns in gene expression. According to research article published in the journal Nature Methods in February 2024, researchers at the University of Toronto have developed a single-cell generative pre-trained transformer (scGPT), an innovative AI model that can efficiently predict the impacts of manipulating specific genes and can integrate different batches of data to detect otherwise untraceable cell types. Moreover, this approach bolsters disease comprehension, drug discovery, and biomarker identification. In addition, machine learning models can project disease outcomes based on transcriptomic data, significantly improving personalized medicine. As the intricacy of transcriptomic data elevates, ML and AI are rapidly becoming requisite for acquiring meaningful insights, positioning this integration as a key trend driving the transcriptomics market growth significantly. Furthermore, the accelerating adoption of AI and ML in transcriptomics is anticipated to boost advancements in precision medicine and targeted therapies, enabling more precise and faster identification of disease mechanisms and novel therapeutic targets.

Advancements in Single-Cell Transcriptomics

The development of single-cell transcriptomics has revolutionized the global transcriptomics market by facilitating the comprehensive study of gene expression at the individual cell level. This trend is rapidly gaining momentum as researchers are actively seeking ways to interpret cellular heterogeneity in various diseases such as neurological disorders and cancer. The growing prevalence of cancer further fuels this trend, as single-cell transcriptomics is requisite for understanding tumor complexity and developing personalized treatments, resultantly contributing to the expansion of transcriptomics market share. According to industry reports, more than 1.9 million new cancer cases were projected to be diagnosed in the U.S. in the year 2023, with 609,820 estimated deaths. Furthermore, single-cell analysis provides an accurate interpretation of cell behavior, resulting in the discovery of innovative biomarkers and new therapeutic targets. In addition, with increasing enhancements in technology and significant reductions in costs, the need for single-cell transcriptomics is substantially accelerating, bolstering the market expansion in both clinical applications and academic research activities.

Increasing Application in Personalized Medicine

The growing integration of transcriptomics in clinical research is transforming treatment protocols across healthcare sectors. The transcriptomics market analysis indicates that this field of study is rapidly being applied in personalized medicine, where comprehending individual gene expression profiles contributes to tailoring treatment methodologies. This trend is primarily propelled by the escalating interest in precision healthcare, especially in rare disorders and cancer. As per industry reports, functional precision medicine can effectively identify effective treatments for almost 55% of adult patients with blood cancers, including lymphoma and leukemia, who have not responded to conventional treatment methods. Moreover, by locating patient-specific biomarkers, transcriptomics facilitates the development of targeted therapies and minimizes the risk of adverse drug reactions. As a result, several healthcare providers as well as pharmaceutical firms are increasingly adopting transcriptomic techniques to formulate individualized treatment strategies. Furthermore, as personalized medicine becomes more prevalent, this field is anticipated to play a crucial role, spurring the demand globally and contributing to a positive transcriptomics market outlook.

Growing Use in Diagnostics and Disease Profiling

The global transcriptomics market is experiencing growth, significantly influenced by the increasing role of transcriptomics in diagnostics and disease profiling, especially in understanding tumor heterogeneity and cancer cell populations. Transcriptome analysis allows researchers to explore the molecular basis of cancer and provides information on tumor progression. Transcriptomic technologies are broadening knowledge about carcinogenesis, the tumor microenvironment, and immuno-oncology, as well as enabled the discovery of new cancer biomarkers. Furthermore, transcriptomic strategies are seeing wide usage in various fields of biomedical research, like disease diagnosis and profiling. RNA-Seq methods enable the extensive identification of transcriptional start sites, reveal alternative promoter utilization, and uncover new splicing changes. In 2024, J INTS BIO announced the launch of an AI-driven alliance to advance cancer therapy. This collaboration, which incorporated transcriptomics along with other multi-omics technologies, aimed to develop personalized lung cancer treatments through AI, enhancing drug efficacy prediction and reducing toxicity.

Transcriptomics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global transcriptomics market, along with forecast at the global, regional, and country levels from 2025-2033. The market has been categorized based on type, technology, application, and end user.

Analysis by Type:

• Instruments
• Consumables
• Software
• Services

Consumables represent the leading segment in the transcriptomics market with 43.8% shares, driven by their essential role in every phase of transcriptomic research. This category includes reagents, kits, probes, and microarrays, which are indispensable for sample preparation, gene expression analysis, and validation. Similarly, the flow of consumables has been triggered by high-throughput sequencing, real-time PCR, and many others all of which require many consumables. Moreover, as the rate of genetic and chronic diseases is on the rise, more research is being carried out which has promoted the recurrent purchase of consumables. The market has also contributed to the growth of the segment because of more efficient kits and reagents for single-cell transcriptomics technology. Besides this, the enhancement in opportunities for personalized medicine and biomarker identification also guarantees the steady growth of consumables’ demand in the future.

Analysis by Technology:

• Microarray
• Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
• Sequencing Technologies

Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) is a leading technology segment in the transcriptomics market due to its unparalleled sensitivity, specificity, and quantification capabilities in gene expression analysis. As a fast and convenient method for confirming data produced by high-throughput sequencing and microarray analysis, Q-PCR is an essential tool of transcriptomics studies. The ability to sample different types as a norm besides the ability to analyse single cells up to tissues also puts the technology in a pole position. Furthermore, heel growth in clinical diagnostics particularly for cancer biomarkers, infective agents, and genetic disorders will augment market growth. Also, constant improvements in Q-PCR reagents, automation procedures, and high throughput platforms have pushed forward the efficiency and reliability of the technique so that it remains a favored technology in the transcriptomics arena.

Key Questions Answered in This Report

• How big is the transcriptomics market?
• What is the future outlook of the transcriptomics market?
• What are the key factors driving the transcriptomics market?
• Which region accounts for the largest transcriptomics market share?
• Which are the leading companies in the global transcriptomics market?